Skip to main content
Premium Trial:

Request an Annual Quote

UNC Hospitals Enters Purchasing Agreement for Devyser Cystic Fibrosis NGS Test

NEW YORK – Devyser Diagnostics announced on Monday that it entered into an estimated SEK 2.5 million ($240,000) annual deal with the University of North Carolina Hospitals to begin buying the company's cystic fibrosis transmembrane conductance regulator next-generation sequencing (CFTR NGS) test.

UNC Hospitals, which comprises NC Memorial Hospital, NC Children’s Hospital, NC Neurosciences Hospital, and NC Women’s Hospital, has agreed to buy the test for up to four years.

The CFTR NGS test, which is approved for research use only in the US and Canada, is designed to capture all published CFTR mutations.

"Devyser CFTR NGS is one of the few products that meet the newly implemented ACMG recommendations," Devyser CEO Fredrik Alpsten said in a statement. "This is the first deal secured for Devyser CFTR NGS in the US, and I am very proud of the entire team who made this happen. We are also very optimistic for the future of Devyser CFTR NGS, especially in the US, where we see a lot of interest."

Earlier this year, Stockholm-based Devyser signed an agreement with Illumina to advance the Swedish company's NGS-based in vitro diagnostics tests on the Illumina MiSeqDx sequencer through regulatory processes in the US and in Europe.

Devyser also entered into a deal last year to grant Thermo Fisher Scientific exclusive rights to commercialize and distribute Devyser's post-transplant tests in North America, Europe, and Brazil.